A Phase II Trial on Osimertinib as a First-Line Treatment for EGFR Mutation-Positive Advanced NSCLC in Elderly Patients: The SPIRAL-0 Study | Zendy

Yusuke Chihara | Zendy; Takayuki Takeda | Zendy; Yasuhiro Gotô | Zendy; Yoichi Nakamura | Zendy; Yuko TsuchiyaKawano | Zendy; Akira Nakao | Zendy; Keisuke Onoi | Zendy; Makoto Hibino | Zendy; Minoru Fukuda | Zendy; Ryoichi Honda | Zendy; Takahiro Yamada | Zendy; Ryusuke Taniguchi | Zendy; Sinjiro Sakamoto | Zendy; Koji Date | Zendy; Seiji Nagashima | Zendy; Shigeru Tanzawa | Zendy; Koichi Minato | Zendy; Koichi Nakatani | Zendy; Miiru Izumi | Zendy; Takayuki Shimose | Zendy; Junji Kishimoto | Zendy; Junji Uchino | Zendy; Koichi Takayama | Zendy

Open Access

A Phase II Trial on Osimertinib as a First-Line Treatment for EGFR Mutation-Positive Advanced NSCLC in Elderly Patients: The SPIRAL-0 Study

Author(s) -

Yusuke Chihara,

Takayuki Takeda,

Yasuhiro Gotô,

Yoichi Nakamura,

Yuko TsuchiyaKawano,

Akira Nakao,

Keisuke Onoi,

Makoto Hibino,

Minoru Fukuda,

Ryoichi Honda,

Takahiro Yamada,

Ryusuke Taniguchi,

Sinjiro Sakamoto,

Koji Date,

Seiji Nagashima,

Shigeru Tanzawa,

Koichi Minato,

Koichi Nakatani,

Miiru Izumi,

Takayuki Shimose,

Junji Kishimoto,

Junji Uchino,

Koichi Takayama

Publication year - 2022

Publication title -

the oncologist

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 2.176

H-Index - 164

eISSN - 1549-490X

pISSN - 1083-7159

DOI - 10.1093/oncolo/oyac193

Subject(s) - osimertinib , medicine , clinical endpoint , pneumonitis , rash , lung cancer , oncology , hazard ratio , erlotinib , discontinuation , adverse effect , phases of clinical research , progression free survival , epidermal growth factor receptor , confidence interval , clinical trial , cancer , lung , chemotherapy

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research